TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype.
Sallman DA, McLemore AF, Aldrich AL, Komrokji RS, McGraw KL, Dhawan A, Geyer S, Hou HA, Eksioglu EA, Sullivan A, Warren S, MacBeth KJ, Meggendorfer M, Haferlach T, Boettcher S, Ebert BL, Al Ali NH, Lancet JE, Cleveland JL, Padron E, List AF.
Sallman DA, et al. Among authors: dhawan a.
Blood. 2020 Dec 10;136(24):2812-2823. doi: 10.1182/blood.2020006158.
Blood. 2020.
PMID: 32730593
Free PMC article.